Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Katharina C Kähler - , Universitätsklinikum Schleswig-Holstein - Campus Lübeck (Author)
  • Dirk Debus - , Klinikum Nurnberg (Author)
  • Gaston Schley - , Helios Klinikum Schwerin (Author)
  • Daniela Göppner - , Justus-Liebig-Universitätsklinikum Gießen (Author)
  • Jessica C Hassel - , University Hospital Heidelberg (Author)
  • Friedegund Meier - , Department of Dermatology, Skin Tumor Center (Author)
  • Patrick Terheyden - , Universitätsklinikum Schleswig-Holstein - Campus Lübeck (Author)
  • Rudolf Stadler - , Universitätsklinik für Dermatologie und Allergologie (Author)
  • Thomas Tüting - , Universitätshautklinik Magdeburg (Author)
  • Martin Kaatz - , SRH Wald-Klinikum Gera (Author)
  • Norman-Philipp Hoff - , University Hospital Duesseldorf (Author)
  • Ehsan Masoudi - , Roche Pharma AG (Author)
  • Agnieszka Zdanowicz-Specht - , Roche Pharma AG (Author)
  • Minh Tam Nguyen - , Roche Pharma AG (Author)
  • Peter Mohr - , Elbe Klinikum Buxtehude (Author)

Abstract

Cobimetinib/vemurafenib combination therapy is approved for treatment of adults with unresectable or metastatic BRAF V600 mutated malignant melanoma (mM). The non-interventional post-authorisation safety study coveNIS collected real-world data on cobimetinib/vemurafenib treatment focussing on overall survival (OS), safety and utilization. MM patients with brain metastases are usually excluded from clinical studies. coveNIS observed 2 cohorts: mM patients without (Cohort A) and with cerebral metastases (Cohort B), aiming to close the data gap for the latter population. A direct comparison of the 2 cohorts was not intended. The primary effectiveness objective was OS; the safety objective was the incidence of all and of serious adverse events (AEs). Secondary objectives included progression-free survival (PFS), time to development of cerebral metastasis (Cohort A) and time to central nervous system relapse (Cohort B). All statistical analyses were descriptive. Between 2017 and 2021, 95 patients were included (Cohort A: 54, Cohort B: 41 patients) at 32 sites in Germany. Median OS was 21.6 months in Cohort A, 7.4 months in Cohort B. Median PFS was 6.9 months in Cohort A, 5.2 months in Cohort B. The proportion of patients experiencing any AEs was 83.3% (Cohort A) and 87.8% (Cohort B). The two most common AEs in Cohort A were 'diarrhoea' (37%), 'vomiting' (20.4%) and 'pyrexia' (20.4%); in Cohort B 'diarrhoea' (36.6%) and 'fatigue' (22%). In conclusion, the OS rates in Cohort A and Cohort B of coveNIS are in line with the OS data from other trials with BRAF/MEK inhibitors for mM. No new safety signals were observed.

Details

Original languageEnglish
Pages (from-to)44-53
Number of pages10
JournalMelanoma research
Volume34
Issue number1
Publication statusPublished - 1 Feb 2024
Peer-reviewedYes

External IDs

PubMedCentral PMC10732299
Scopus 85181016901
ORCID /0000-0003-4340-9706/work/151982832

Keywords

Keywords

  • Adult, Humans, Vemurafenib/pharmacology, Melanoma/drug therapy, Proto-Oncogene Proteins B-raf/genetics, Skin Neoplasms/pathology, Mutation, Neoplasm Recurrence, Local/drug therapy, Protein Kinase Inhibitors/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects